Naltrexone decreases heavy drinking rates in smoking cessation treatment: An exploratory study

Alcoholism: Clinical and Experimental Research

Volumn 33, Issue 6, 2009, Pages 1044-1050

  King, Andrea ^a,b   Cao, Dingcai ^b   Vanier, Catherine ^a   Wilcox, Tracie ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alcohol; Binge drinking; Heavy drinking; Liver; Naltrexone; Smoking cessation

Indexed keywords

CQ; NALTREXONE; NICOTINE; NICOTINE PATCH; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ALCOHOL DRINKING; ASPARTATE AMINOTRANSFERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 66549107604     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2009.00925.x     Document Type: Article

References (48)

1. Acheson A, Mahler SV, Chi H, de Wit H (2006) Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology 186 : 54 63. (Pubitemid 43668311)
2. Allen JP, Litten RZ, Strid N, Sillanaukee P (2001) The role of biomarkers in alcoholism medication trials. Alcohol Clin Exp Res 25 : 1119 1125. (Pubitemid 32761718)
3. Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51 : 1173 1182.
4. Berg BJ, Pettinati HM, Volpicelli JR (1996) A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 15 : 274 282. (Pubitemid 26358589)
5. Borland R (1990) Slip-ups and relapse in attempts to quit smoking. Addict Behav 15 : 235 245. (Pubitemid 20335771)
6. Carmen B, Angeles M, Ana M, Maria AJ (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99 : 811 828. (Pubitemid 38869838)
7. Covey LS, Glassman AH, Stetner F (1999) Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 18 : 31 40. (Pubitemid 29231718)
8. Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 54 : 1130 1135.
9. David S, Lancaster T, Stead LF, Evins AE (2006) Opioid antagonist for smoking cessation. Cochrane Database Syst Rev 4 : CD-0003086. DOI :.
10. Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23 : 195 203. (Pubitemid 29100390)
11. Davidson D, Swift R, Fitz E (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20 : 732 739. (Pubitemid 26186942)
12. Epstein AM, Sher TG, Young MA, King AC (2007) Tobacco chippers show robust increases in smoking urge after alcohol consumption. Psychopharmacology 190 : 321 329. (Pubitemid 46155641)
13. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton CG, Henderson PN, Heyman RB, Koh HK, Kottke TE, Lando HA, Mecklenburg RE, Mermelstein RJ, Mullen PD, Orleans CT, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME (2008) Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. U.S. Department of Health and Human Services, Public Health Service, Rockville, MD.
14. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York.
15. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstromm K (1991) The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 86 : 1119 1127.
16. Hughes JR, Kelly JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE (2003) Measures of abstinence in clinical trials: issues and recommendation. Nicotine Tob Res 5 : 13 25. (Pubitemid 36285465)
17. King AC, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D (2006) Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res 5 : 1 12.
18. King AC, Epstein AM (2005) Alcohol dose-dependent increases in smoking urge in light smokers. Alcohol Clin Exp Res 29 : 547 552. (Pubitemid 40547857)
19. King AC, Riley R (2001) Stop Smoking Manual. The University of Chicago Studies on Smoking Cessation. University of Chicago, Chicago, IL.
20. King AC, Torello R, Krishnan-Sarin S, O'Malley SS (2009) Naltrexone in smoking cessation: a review of the literature and future directions, in Opioid Receptors and Antagonists: From Bench to Clinic (Dean R, Bilsky E, Negus S, eds pp 307 324. Humana Press, Totowa, NJ.
21. King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ (1997) Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 21 : 906 909. (Pubitemid 27355690)
22. Krishnan-Sarin S, Rosen MI, O'Malley SS (1999) Naloxone challenge in smokers: preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 56 : 663 668. (Pubitemid 29315639)
23. Lee DH, Ha MH, Christiani DC (2001) Body weight, alcohol consumption and liver enzyme activity - a 4-year follow-up study. Int J Epidemiol 30 : 766 770. (Pubitemid 32827381)
24. Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73 : 13 22.
25. McKee SA, Krishnan-Sarin K, O'Malley S, Harrison E, Shi J, Tetrault J, Estevez N (2008a) Effect of varenicline, a partial nicotinic agonist, on alcohol self-administration in heavy drinking smokers. Alcohol Clin Exp Res 32 : 302A.
26. McKee SA, O'Malley SS, Shi J, Mase T, Krishnan-Sarin S (2008b) Transdermal nicotine replacement attenuates alcohol reactivity and reduces alcohol self-administration. Psychopharmacology 196 : 189 200.
27. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D (1987) High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 22 : 35 42. (Pubitemid 17229950)
28. O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P (2006) A controlled trial of naltrexone augmentation of nicotine replacement for smoking cessation. Arch Intern Med 166 : 667 674.
29. O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ (1996) Experience of a "slip" among alcoholics treated with naltrexone or placebo. Am J Psych 153 : 281 283.
30. O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW (2008) Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int J Neuropsychopharmacol 17 : 1 9.
31. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SM, Oslin DW, Kampman KM, Dackis CA (2006) The status of naltrexone in the treatment of alcohol dependence. J Clin Psychopharmacol 26 : 610 625.
32. Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, Morley JE (1986) Naltrexone hydrochloride (Traxan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr 67 : 66 72. (Pubitemid 17193505)
33. Ray LA, Miranda R, Kahler CW, Leventhal AM, Monti PM, Swift R, Hutchison KE (2007) Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharm 193 : 449 456. (Pubitemid 47094371)
34. Rohsenow D, Monti P, Colby S, Gulliver S, Swift R, Abrams D (2003) Naltrexone treatment for alcoholics: effect on cigarette smoking rates. Nicotine Tob Res 5 : 231 236. (Pubitemid 36547006)
35. SAMHSA (2005) National Survey on Drug Use and Health. Office of Applied Studies, Bethesda, MD.
36. Shiffman SM, Fischer LA, Paty J, Gnys M, Hickcox M, Kassel JD (1994) Drinking and smoking: a field study of their association. Ann Behav Med 16 : 203 209. (Pubitemid 24280824)
37. Shiffman S, Paty JA, Kassel JA, Hickcox M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64 : 366 379. (Pubitemid 26131633)
38. Sobell LC, Maisto SA, Sobell MB, Cooper AM (1979) Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther 17 : 157 160. (Pubitemid 9128763)
39. Sobell LC, Sobell MB (1995) Alcohol Timeline Follow-Back Users' Manual. Addiction Research Foundation, Toronto, ON.
40. Srisurapanont M, Jarusuraisin N (2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 1 : CD-001867. DOI :.
41. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. PNAS 104 : 12518 12523. (Pubitemid 47206170)
42. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151 : 1463 1467. (Pubitemid 24301690)
43. Tantcheva-Poor I, Zaigler M, Rietbrocks S, Fuhr U (1999) Estimation of cytochrome P450 CYP1A2 activity in 863 health Caucasians using a saliva-based caffeine test. Pharmacogenetics 9 : 131 144. (Pubitemid 29358995)
44. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32 : 58 66. (Pubitemid 350293891)
45. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 : 876 880.
46. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 54 : 737 742. (Pubitemid 27344101)
47. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brian CP (1995) Effect of naltrexone on alcohol "High" in alcoholics. Am J Psychiatry 152 : 613 615.
48. Walsh Z, Epstein A, Munisamy G, King A (2008) The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis 27 : 65 72.